Cargando…
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC
Immune checkpoint blockades (ICBs) have changed the standard of care of squamous and adenocarcinoma non‐small cell lung cancer (NSCLC). Whereas detailed researches regarding ICBs in the two major histological subtypes are rare. In order to uncover the clinical efficacy differences between squamous a...
Autores principales: | Tian, Yaru, Zhai, Xiaoyang, Yan, Weiwei, Zhu, Hui, Yu, Jinming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826453/ https://www.ncbi.nlm.nih.gov/pubmed/33230935 http://dx.doi.org/10.1002/cam4.3590 |
Ejemplares similares
-
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
por: Tian, Yaru, et al.
Publicado: (2019) -
Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
por: Cha, Edward, et al.
Publicado: (2013) -
The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023) -
Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
por: Buchbinder, Elizabeth I., et al.
Publicado: (2021) -
Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
por: Tian, Yaru, et al.
Publicado: (2019)